

Chuan-bao Zhang

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8433347/publications.pdf>

Version: 2024-02-01

114
papers

5,917
citations

101543

36
h-index

85541

71
g-index

116
all docs

116
docs citations

116
times ranked

7404
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 1 | CGCG clinical practice guidelines for the management of adult diffuse gliomas. <i>Cancer Letters</i> , 2016, 375, 263-273. | 7.2 | 448 |
| 2 | Chinese Glioma Genome Atlas (CGGA): A Comprehensive Resource with Functional Genomic Data from Chinese Glioma Patients. <i>Genomics, Proteomics and Bioinformatics</i> , 2021, 19, 1-12. | 6.9 | 439 |
| 3 | Tumor Purity as an Underlying Key Factor in Glioma. <i>Clinical Cancer Research</i> , 2017, 23, 6279-6291. | 7.0 | 372 |
| 4 | RNA-seq of 272 gliomas revealed a novel, recurrent <i>PTPRZ1-MET</i> fusion transcript in secondary glioblastomas. <i>Genome Research</i> , 2014, 24, 1765-1773. | 5.5 | 316 |
| 5 | Mutational Landscape of Secondary Glioblastoma Guides MET-Targeted Trial in Brain Tumor. <i>Cell</i> , 2018, 175, 1665-1678.e18. | 28.9 | 250 |
| 6 | Bioinformatic profiling identifies an immune-related risk signature for glioblastoma. <i>Neurology</i> , 2016, 86, 2226-2234. | 1.1 | 234 |
| 7 | Comprehensive RNA-seq transcriptomic profiling in the malignant progression of gliomas. <i>Scientific Data</i> , 2017, 4, 170024. | 5.3 | 208 |
| 8 | Clinical practice guidelines for the management of adult diffuse gliomas. <i>Cancer Letters</i> , 2021, 499, 60-72. | 7.2 | 194 |
| 9 | Stabilization of phosphofructokinase 1 platelet isoform by AKT promotes tumorigenesis. <i>Nature Communications</i> , 2017, 8, 949. | 12.8 | 191 |
| 10 | Phosphoglycerate Kinase 1 Phosphorylates Beclin1 to Induce Autophagy. <i>Molecular Cell</i> , 2017, 65, 917-931.e6. | 9.7 | 190 |
| 11 | Molecular and clinical characterization of PD-L1 expression at transcriptional level via 976 samples of brain glioma. <i>Oncolmmunology</i> , 2016, 5, e1196310. | 4.6 | 176 |
| 12 | Differentiation of glioblastoma from solitary brain metastases using radiomic machine-learning classifiers. <i>Cancer Letters</i> , 2019, 451, 128-135. | 7.2 | 128 |
| 13 | EGFR-Phosphorylated Platelet Isoform of Phosphofructokinase 1 Promotes PI3K Activation. <i>Molecular Cell</i> , 2018, 70, 197-210.e7. | 9.7 | 116 |
| 14 | Molecular and clinical characterization of TIM-3 in glioma through 1,024 samples. <i>Oncolmmunology</i> , 2017, 6, e1328339. | 4.6 | 114 |
| 15 | PTEN Suppresses Glycolysis by Dephosphorylating and Inhibiting Autophosphorylated PCK1. <i>Molecular Cell</i> , 2019, 76, 516-527.e7. | 9.7 | 113 |
| 16 | Ferroptosis-Related Gene Signature Predicts Glioma Cell Death and Glioma Patient Progression. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 538. | 3.7 | 105 |
| 17 | HOTAIR is a therapeutic target in glioblastoma. <i>Oncotarget</i> , 2015, 6, 8353-8365. | 1.8 | 105 |
| 18 | CMTM6 overexpression is associated with molecular and clinical characteristics of malignancy and predicts poor prognosis in gliomas. <i>EBioMedicine</i> , 2018, 35, 233-243. | 6.1 | 97 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 19 | Genetic and clinical characterization of B7 β (CD276) expression and epigenetic regulation in diffuse brain glioma. <i>Cancer Science</i> , 2018, 109, 2697-2705. | 3.9 | 73 |
| 20 | Prognostic value of a microRNA signature as a novel biomarker in patients with lower-grade gliomas. <i>Journal of Neuro-Oncology</i> , 2018, 137, 127-137. | 2.9 | 66 |
| 21 | ATRX mRNA expression combined with IDH1/2 mutational status and Ki-67 expression refines the molecular classification of astrocytic tumors: evidence from the whole transcriptome sequencing of 169 samples. <i>Oncotarget</i> , 2014, 5, 2551-2561. | 1.8 | 61 |
| 22 | Identification of a 6-Cytokine Prognostic Signature in Patients with Primary Glioblastoma Harboring M2 Microglia/Macrophage Phenotype Relevance. <i>PLoS ONE</i> , 2015, 10, e0126022. | 2.5 | 59 |
| 23 | Correlation of IDH1/2 mutation with clinicopathologic factors and prognosis in anaplastic gliomas: a report of 203 patients from China. <i>Journal of Cancer Research and Clinical Oncology</i> , 2014, 140, 45-51. | 2.5 | 57 |
| 24 | Relationship between necrotic patterns in glioblastoma and patient survival: fractal dimension and lacunarity analyses using magnetic resonance imaging. <i>Scientific Reports</i> , 2017, 7, 8302. | 3.3 | 55 |
| 25 | Upregulation of long noncoding RNA HOXA-AS3 promotes tumor progression and predicts poor prognosis in glioma. <i>Oncotarget</i> , 2017, 8, 53110-53123. | 1.8 | 55 |
| 26 | MicroRNA expression patterns in the malignant progression of gliomas and a 5-microRNA signature for prognosis. <i>Oncotarget</i> , 2014, 5, 12908-12915. | 1.8 | 54 |
| 27 | Detection of ATRX and IDH1-R132H immunohistochemistry in the progression of 211 paired gliomas. <i>Oncotarget</i> , 2016, 7, 16384-16395. | 1.8 | 53 |
| 28 | Molecular and clinical characterization of IDH associated immune signature in lower-grade gliomas. <i>Oncol Immunology</i> , 2018, 7, e1434466. | 4.6 | 53 |
| 29 | miR-181d/MALT1 regulatory axis attenuates mesenchymal phenotype through NF- κ B pathways in glioblastoma. <i>Cancer Letters</i> , 2017, 396, 1-9. | 7.2 | 50 |
| 30 | A five-miRNA signature with prognostic and predictive value for <i>MGMT</i> promoter-methylated glioblastoma patients. <i>Oncotarget</i> , 2015, 6, 29285-29295. | 1.8 | 49 |
| 31 | Loss of ATRX, associated with DNA methylation pattern of chromosome end, impacted biological behaviors of astrocytic tumors. <i>Oncotarget</i> , 2015, 6, 18105-18115. | 1.8 | 48 |
| 32 | ATRX, IDH1-R132H and Ki-67 immunohistochemistry as a classification scheme for astrocytic tumors. <i>Oncoscience</i> , 2016, 3, 258-265. | 2.2 | 42 |
| 33 | ALDH1A3 induces mesenchymal differentiation and serves as a predictor for survival in glioblastoma. <i>Cell Death and Disease</i> , 2018, 9, 1190. | 6.3 | 42 |
| 34 | Gene Expression Profiling Stratifies IDH1-Mutant Glioma with Distinct Prognoses. <i>Molecular Neurobiology</i> , 2017, 54, 5996-6005. | 4.0 | 41 |
| 35 | Genetic and clinical characteristics of primary and secondary glioblastoma is associated with differential molecular subtype distribution. <i>Oncotarget</i> , 2015, 6, 7318-7324. | 1.8 | 40 |
| 36 | ISG20 promotes local tumor immunity and contributes to poor survival in human glioma. <i>Oncol Immunology</i> , 2019, 8, e1534038. | 4.6 | 39 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 37 | Identification of PIEZO1 as a potential prognostic marker in gliomas. <i>Scientific Reports</i> , 2020, 10, 16121. | 3.3 | 39 |
| 38 | Identification of high risk anaplastic gliomas by a diagnostic and prognostic signature derived from mRNA expression profiling. <i>Oncotarget</i> , 2015, 6, 36643-36651. | 1.8 | 39 |
| 39 | PD-1 related transcriptome profile and clinical outcome in diffuse gliomas. <i>Oncolmmunology</i> , 2018, 7, e1382792. | 4.6 | 37 |
| 40 | HDAC4, a prognostic and chromosomal instability marker, refines the predictive value of MGMT promoter methylation. <i>Journal of Neuro-Oncology</i> , 2015, 122, 303-312. | 2.9 | 36 |
| 41 | Multidimensional analysis of gene expression reveals TGF β 11-induced EMT contributes to malignant progression of astrocytomas. <i>Oncotarget</i> , 2014, 5, 12593-12606. | 1.8 | 36 |
| 42 | Immune Cytolytic Activity Is Associated With Genetic and Clinical Properties of Glioma. <i>Frontiers in Immunology</i> , 2019, 10, 1756. | 4.8 | 35 |
| 43 | KIF23 is an independent prognostic biomarker in glioma, transcriptionally regulated by TCF-4. <i>Oncotarget</i> , 2016, 7, 24646-24655. | 1.8 | 33 |
| 44 | BMP4, a strong better prognosis predictor, has a subtype preference and cell development association in gliomas. <i>Journal of Translational Medicine</i> , 2013, 11, 100. | 4.4 | 32 |
| 45 | Overexpression of Paxillin Correlates with Tumor Progression and Predicts Poor Survival in Glioblastoma. <i>CNS Neuroscience and Therapeutics</i> , 2017, 23, 69-75. | 3.9 | 32 |
| 46 | PD-L2 expression is correlated with the molecular and clinical features of glioma, and acts as an unfavorable prognostic factor. <i>Oncolmmunology</i> , 2019, 8, e1541535. | 4.6 | 32 |
| 47 | Clinicopathological factors predictive of postoperative seizures in patients with gliomas. <i>Seizure: the Journal of the British Epilepsy Association</i> , 2016, 35, 93-99. | 2.0 | 31 |
| 48 | High expression of CXCR3 is an independent prognostic factor in glioblastoma patients that promotes an invasive phenotype. <i>Journal of Neuro-Oncology</i> , 2015, 122, 43-51. | 2.9 | 29 |
| 49 | Low c-Met expression levels are prognostic for and predict the benefits of temozolomide chemotherapy in malignant gliomas. <i>Scientific Reports</i> , 2016, 6, 21141. | 3.3 | 29 |
| 50 | Isocitrate dehydrogenase 1 Gene Mutation Is Associated with Prognosis in Clinical Low-Grade Gliomas. <i>PLoS ONE</i> , 2015, 10, e0130872. | 2.5 | 28 |
| 51 | ADAM9 Expression Is Associate with Glioma Tumor Grade and Histological Type, and Acts as a Prognostic Factor in Lower-Grade Gliomas. <i>International Journal of Molecular Sciences</i> , 2016, 17, 1276. | 4.1 | 27 |
| 52 | Peripheral blood test provides a practical method for glioma evaluation and prognosis prediction. <i>CNS Neuroscience and Therapeutics</i> , 2019, 25, 876-883. | 3.9 | 27 |
| 53 | Genome-wide transcriptional analyses of Chinese patients reveal cell migration is attenuated in IDH1-mutant glioblastomas. <i>Cancer Letters</i> , 2015, 357, 566-574. | 7.2 | 25 |
| 54 | Rab27a Was Identified as a Prognostic Biomaker by mRNA Profiling, Correlated with Malignant Progression and Subtype Preference in Gliomas. <i>PLoS ONE</i> , 2014, 9, e89782. | 2.5 | 22 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 55 | Identification of a five B cell-associated gene prognostic and predictive signature for advanced glioma patients harboring immunosuppressive subtype preference. <i>Oncotarget</i> , 2016, 7, 73971-73983. | 1.8 | 22 |
| 56 | Progress on molecular biomarkers and classification of malignant gliomas. <i>Frontiers of Medicine</i> , 2013, 7, 150-156. | 3.4 | 21 |
| 57 | Anatomical specificity of O6-methylguanine DNA methyltransferase protein expression in glioblastomas. <i>Journal of Neuro-Oncology</i> , 2014, 120, 331-337. | 2.9 | 21 |
| 58 | Association between small heat shock protein B11 and the prognostic value of MGMT promoter methylation in patients with high-grade glioma. <i>Journal of Neurosurgery</i> , 2016, 125, 7-16. | 1.6 | 20 |
| 59 | Treatment strategy and IDH status improve nomogram validity in newly diagnosed GBM patients. <i>Neuro-Oncology</i> , 2017, 19, 736-738. | 1.2 | 20 |
| 60 | Bioinformatic analyses reveal a distinct Notch activation induced by STAT3 phosphorylation in the mesenchymal subtype of glioblastoma. <i>Journal of Neurosurgery</i> , 2017, 126, 249-259. | 1.6 | 19 |
| 61 | Expression of SPRR3 is associated with tumor cell proliferation and invasion in glioblastoma multiforme. <i>Oncology Letters</i> , 2014, 7, 427-432. | 1.8 | 18 |
| 62 | MR imaging based fractal analysis for differentiating primary CNS lymphoma and glioblastoma. <i>European Radiology</i> , 2019, 29, 1348-1354. | 4.5 | 18 |
| 63 | Comprehensive analysis of the immunological landscape of pituitary adenomas: implications of immunotherapy for pituitary adenomas. <i>Journal of Neuro-Oncology</i> , 2020, 149, 473-487. | 2.9 | 18 |
| 64 | Prognostic value of a nine-gene signature in glioma patients based on tumor-associated macrophages expression profiling. <i>Clinical Immunology</i> , 2020, 216, 108430. | 3.2 | 18 |
| 65 | Integrated analysis of genome-wide DNA methylation, gene expression and protein expression profiles in molecular subtypes of WHO II-IV gliomas. <i>Journal of Experimental and Clinical Cancer Research</i> , 2015, 34, 127. | 8.6 | 17 |
| 66 | miR-17-5p-CXCL14 axis related transcriptome profile and clinical outcome in diffuse gliomas. <i>Oncolimmunology</i> , 2018, 7, e1510277. | 4.6 | 17 |
| 67 | Hypomethylated Rab27b is a progression-associated prognostic biomarker of glioma regulating MMP-9 to promote invasion. <i>Oncology Reports</i> , 2015, 34, 1503-1509. | 2.6 | 16 |
| 68 | Deficiency of very large G-protein-coupled receptor-1 is a risk factor of tumor-related epilepsy: a whole transcriptome sequencing analysis. <i>Journal of Neuro-Oncology</i> , 2015, 121, 609-616. | 2.9 | 16 |
| 69 | Expression and prognostic value of microRNAs in lower-grade glioma depends on IDH1/2 status. <i>Journal of Neuro-Oncology</i> , 2017, 132, 207-218. | 2.9 | 16 |
| 70 | CLDN5 affects lncRNAs acting as ceRNA dynamics contributing to regulating blood-brain barrier permeability in tumor brain metastasis. <i>Oncology Reports</i> , 2018, 39, 1441-1453. | 2.6 | 16 |
| 71 | Molecular and clinical characterization of PTPN2 expression from RNA-seq data of 996 brain gliomas. <i>Journal of Neuroinflammation</i> , 2018, 15, 145. | 7.2 | 15 |
| 72 | Glioma-related epilepsy in patients with diffuse high-grade glioma after the 2016 WHO update: seizure characteristics, risk factors, and clinical outcomes. <i>Journal of Neurosurgery</i> , 2022, 136, 67-75. | 1.6 | 15 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 73 | CTLA4-Mediated Immunosuppression in Glioblastoma is Associated with the Infiltration of Macrophages in the Tumor Microenvironment. <i>Journal of Inflammation Research</i> , 2021, Volume 14, 7315-7329. | 3.5 | 15 |
| 74 | <i>PABPC1</i> relevant bioinformatic profiling and prognostic value in gliomas. <i>Future Oncology</i> , 2020, 16, 4279-4288. | 2.4 | 14 |
| 75 | Epigenetic silencing of KAZALD1 confers a better prognosis and is associated with malignant transformation/progression in glioma. <i>Oncology Reports</i> , 2013, 30, 2089-2096. | 2.6 | 13 |
| 76 | T-Cell Exhaustion Status Under High and Low Levels of Hypoxia-Inducible Factor 1 α Expression in Glioma. <i>Frontiers in Pharmacology</i> , 2021, 12, 711772. | 3.5 | 13 |
| 77 | Integrated analysis using methylation and gene expression microarrays reveals PDE4C as a prognostic biomarker in human glioma. <i>Oncology Reports</i> , 2014, 32, 250-260. | 2.6 | 12 |
| 78 | The Landscape of Viral Expression Reveals Clinically Relevant Viruses with Potential Capability of Promoting Malignancy in Lower-Grade Glioma. <i>Clinical Cancer Research</i> , 2017, 23, 2177-2185. | 7.0 | 12 |
| 79 | Identification of a Glycolysis-Related LncRNA Signature to Predict Survival in Diffuse Glioma Patients. <i>Frontiers in Oncology</i> , 2020, 10, 597877. | 2.8 | 12 |
| 80 | Human leukocyte antigen-G overexpression predicts poor clinical outcomes in low-grade gliomas. <i>Journal of Neuroimmunology</i> , 2016, 294, 27-31. | 2.3 | 11 |
| 81 | Co-expression of mitosis-regulating genes contributes to malignant progression and prognosis in oligodendrogliomas. <i>Oncotarget</i> , 2015, 6, 38257-38269. | 1.8 | 11 |
| 82 | Phosphohistone H3 (pHH3) is a prognostic and epithelial to mesenchymal transition marker in diffuse gliomas. <i>Oncotarget</i> , 2016, 7, 45005-45014. | 1.8 | 10 |
| 83 | FGFR3, as a receptor tyrosine kinase, is associated with differentiated biological functions and improved survival of glioma patients. <i>Oncotarget</i> , 2016, 7, 84587-84593. | 1.8 | 10 |
| 84 | Co-expression modules of NF1, PTEN and sprouty enable distinction of adult diffuse gliomas according to pathway activities of receptor tyrosine kinases. <i>Oncotarget</i> , 2016, 7, 59098-59114. | 1.8 | 10 |
| 85 | Brain regions associated with telomerase reverse transcriptase promoter mutations in primary glioblastomas. <i>Journal of Neuro-Oncology</i> , 2016, 128, 455-462. | 2.9 | 9 |
| 86 | MEGF10, a Glioma Survival-Associated Molecular Signature, Predicts IDH Mutation Status. <i>Disease Markers</i> , 2018, 2018, 1-8. | 1.3 | 9 |
| 87 | MicroRNA-935 Directly Targets FZD6 to Inhibit the Proliferation of Human Glioblastoma and Correlate to Glioma Malignancy and Prognosis. <i>Frontiers in Oncology</i> , 2021, 11, 566492. | 2.8 | 9 |
| 88 | Pre-treatment neutrophils count as a prognostic marker to predict chemotherapeutic response and survival outcomes in glioma: a single-center analysis of 288 cases. <i>American Journal of Translational Research (discontinued)</i> , 2020, 12, 90-104. | 0.0 | 9 |
| 89 | Apcin inhibits the growth and invasion of glioblastoma cells and improves glioma sensitivity to temozolomide. <i>Bioengineered</i> , 2021, 12, 10791-10798. | 3.2 | 9 |
| 90 | Identification of IDH-mutant gliomas by a prognostic signature according to gene expression profiling. <i>Aging</i> , 2018, 10, 1977-1988. | 3.1 | 8 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 91 | Stratification according to recursive partitioning analysis predicts outcome in newly diagnosed glioblastomas. <i>Oncotarget</i> , 2017, 8, 42974-42982. | 1.8 | 8 |
| 92 | A PTEN-COL17A1 fusion gene and its novel regulatory role in Collagen XVII expression and GBM malignance. <i>Oncotarget</i> , 2017, 8, 85794-85803. | 1.8 | 8 |
| 93 | Highly sensitive clinical diagnostic method for PTPRZ1-MET and the characteristic protein structure contributing to ligand-independent MET activation. <i>CNS Neuroscience and Therapeutics</i> , 2021, 27, 617-628. | 3.9 | 7 |
| 94 | Polo-like kinases as potential targets and PLK2 as a novel biomarker for the prognosis of human glioblastoma. <i>Aging</i> , 2022, 14, 2320-2334. | 3.1 | 7 |
| 95 | MiR-134, epigenetically silenced in gliomas, could mitigate the malignant phenotype by targeting KRAS. <i>Carcinogenesis</i> , 2018, 39, 389-396. | 2.8 | 6 |
| 96 | Predicting chromosome 1p/19q codeletion by RNA expression profile: a comparison of current prediction models. <i>Aging</i> , 2019, 11, 974-985. | 3.1 | 5 |
| 97 | Novel roles of VAT1 expression in the immunosuppressive action of diffuse gliomas. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 2589-2600. | 4.2 | 5 |
| 98 | Comparative profiling of immune genes improves the prognoses of lower grade gliomas. <i>Cancer Biology and Medicine</i> , 2021, 18, 0-0. | 3.0 | 5 |
| 99 | Predicting the likelihood of early recurrence based on mRNA sequencing of pituitary adenomas. <i>Gland Surgery</i> , 2019, 8, 648-656. | 1.1 | 4 |
| 100 | Characterization and prognostic significance of alternative splicing events in lower-grade diffuse gliomas. <i>Journal of Cellular and Molecular Medicine</i> , 2020, 24, 13171-13180. | 3.6 | 4 |
| 101 | Long-term efficacy of surgical resection with or without adjuvant therapy for treatment of secondary glioblastoma in adults. <i>Neuro-Oncology Advances</i> , 2020, 2, vdaa098. | 0.7 | 4 |
| 102 | Consistency of pituitary adenomas: Amounts of collagen types I and III and the predictive value of T2WI MRI. <i>Experimental and Therapeutic Medicine</i> , 2021, 22, 1255. | 1.8 | 4 |
| 103 | Integrated analysis identified genes associated with a favorable prognosis in oligodendrogliomas. <i>Genes Chromosomes and Cancer</i> , 2016, 55, 169-176. | 2.8 | 3 |
| 104 | New-Onset Postoperative Seizures in Patients With Diffuse Gliomas: A Risk Assessment Analysis. <i>Frontiers in Neurology</i> , 2021, 12, 682535. | 2.4 | 3 |
| 105 | Radiation combined with temozolomide contraindicated for young adults diagnosed with anaplastic glioma. <i>Oncotarget</i> , 2016, 7, 80091-80100. | 1.8 | 2 |
| 106 | Expression changes in ion channel and immunity genes are associated with glioma-related epilepsy in patients with diffuse gliomas. <i>Journal of Cancer Research and Clinical Oncology</i> , 2022, 148, 2793-2802. | 2.5 | 2 |
| 107 | Predicting the likelihood of postoperative seizure status based on mRNA sequencing in low-grade gliomas. <i>Future Oncology</i> , 2018, 14, 545-552. | 2.4 | 1 |
| 108 | Hemangiopericytomas: Spatial Intracranial Location in a Voxel-Based Mapping Study. <i>Journal of Neuroimaging</i> , 2020, 30, 370-377. | 2.0 | 1 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 109 | CPNE3 regulates the cell proliferation and apoptosis in human Glioblastoma via the activation of PI3K/AKT signaling pathway. <i>Journal of Cancer</i> , 2021, 12, 7277-7286. | 2.5 | 1 |
| 110 | Comprehensive analysis of the LncRNAs, MiRNAs, and MRNAs acting within the competing endogenous RNA network of LGG. <i>Genetica</i> , 2022, 150, 41. | 1.1 | 1 |
| 111 | Whole-transcriptome sequencing profiling identifies functional and prognostic signatures in patients with PTPRZ1-MET fusion-negative secondary glioblastoma multiforme. <i>Oncology Letters</i> , 2020, 20, 1-1. | 1.8 | 1 |
| 112 | Whole-transcriptome sequencing profiling identifies functional and prognostic signatures in patients with PTPRZ1-MET fusion-negative secondary glioblastoma multiforme. <i>Oncology Letters</i> , 2020, 20, 187. | 1.8 | 0 |
| 113 | Targeted exome sequencing for the identification of common mutational signatures and potential driver mutations for brain metastases and prognosis. <i>Oncology Letters</i> , 2021, 21, 179. | 1.8 | 0 |
| 114 | Long-term adjuvant administration of temozolomide impacts serum ions concentration in high-grade glioma. <i>Chinese Neurosurgical Journal</i> , 2022, 8, 6. | 0.9 | 0 |